Add-on-CBD reduzierte die monatliche Anfallsfrequenz bei therapieresistenter Epilepsie um etwa 50% über den gesamten Beobachtungszeitraum.
Zusammenfassung
n=607 Patienten mit therapierefraktärer Epilepsie, Add-on-CBD (median 25 mg/kg/d) über median 48 Wochen; mediane monatliche konvulsive Anfallsfrequenz um 51% reduziert, Gesamtanfälle um 48% nach 12 Wochen; ≥50%/≥75%/100%-Responder (konvulsiv): 52%/31%/11%; 24% brachen ab (15% Wirklosigkeit, 5% UAW). Effekte blieben stabil bis Woche 96.
P
PopulationKinder und Erwachsene mit therapieresistenten Epilepsien (TRE), n=607, mittleres Alter 13 Jahre (0,4–62 Jahre), mediane Anzahl begleitender AEDs: 3
I
InterventionOrales Cannabidiol (CBD) als Add-on, Startdosis 2–10 mg/kg/d, titriert bis max. 25–50 mg/kg/d (Median 25 mg/kg/d), mediane Behandlungsdauer 48 Wochen
O
OutcomeReduktion der medianen monatlichen konvulsiven Anfälle um 51% und der Gesamtanfälle um 48% nach 12 Wochen; ähnliche Reduktionen bis Woche 96; 52% der Patienten erreichten ≥50%-Reduktion konvulsiver Anfälle
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Qualitätsprofil
Größe★★★★★
Verblindung—
EffektstärkeKlarer Nutzen
Zitate / Jahr★★★★★
Autoren
Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R, CBD EAP study group.
<h4>Objective</h4>Since 2014, cannabidiol (CBD) has been administered to patients with treatment-resistant epilepsies (TREs) in an ongoing expanded-access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016.<h4>Methods</h4>Twenty-five US-based EAP sites enrolling patients with TRE taking stable doses of antiepileptic drugs (AEDs) at baseline were included. During the 4-week baseline period, parents/caregivers kept diaries of all countable seizure types. Patients received oral CBD starting at 2-10 mg/kg/d, titrated to a maximum dose of 25-50 mg/kg/d. Patient visits were every 2-4 weeks through 16 weeks and every 2-12 weeks thereafter. Efficacy endpoints included the percentage change from baseline in median monthly convulsive and total seizure frequency, and percentage of patients with ≥50%, ≥75%, and 100% reductions in seizures vs baseline. Data were analyzed descriptively for the efficacy analysis set and using the last-observation-carried-forward method to account for missing data. Adverse events (AEs) were documented at each visit.<h4>Results</h4>Of 607 patients in the safety dataset, 146 (24%) withdrew; the most common reasons were lack of efficacy (89 [15%]) and AEs (32 [5%]). Mean age was 13 years (range, 0.4-62). Median number of concomitant AEDs was 3 (range, 0-10). Median CBD dose was 25 mg/kg/d; median treatment duration was 48 weeks. Add-on CBD reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks; reductions were similar through 96 weeks. Proportion of patients with ≥50%, ≥75%, and 100% reductions in convulsive seizures were 52%, 31%, and 11%, respectively, at 12 weeks, with similar rates through 96 weeks. CBD was generally well tolerated; most common AEs were diarrhea (29%) and somnolence (22%).<h4>Significance</h4>Results from this ongoing EAP support previous observational and clinical trial data showing that add-on CBD may be an efficacious long-term treatment option for TRE.